Literature DB >> 14673583

The cerebellum and cognition. Intellectual function in spinocerebellar ataxia type 6 (SCA6).

C Globas1, S Bösch, Ch Zühlke, I Daum, J Dichgans, K Bürk.   

Abstract

The aim of this study was to assess cognitive function in patients with spinocerebellar ataxia type 6 (SCA6), an autosomal-dominantly inherited disease leading to a progressive cerebellar syndrome. In contrast to other SCA types, the pathological changes are mostly restricted to the cerebellum. Cognitive function was studied in 12 patients with genetically confirmed SCA6 (mean duration of disease: 9.2 +/- 11.6 years) and 12 age- and IQ-matched controls using a test battery comprising tests for IQ, attention, verbal and visuospatial memory, as well as executive function. While none of the SCA6 subjects had features of general intellectual impairment, only mild deficits in single subtests especially in fronto-executive tasks were observed, but without reaching statistical significance. Thus the current findings do not demonstrate severe cognitive dysfunction in SCA6.

Entities:  

Mesh:

Year:  2003        PMID: 14673583     DOI: 10.1007/s00415-003-0258-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Reduced phonological similarity effects in patients with damage to the cerebellum.

Authors:  Timothy Justus; Susan M Ravizza; Julie A Fiez; Richard B Ivry
Journal:  Brain Lang       Date:  2005-11       Impact factor: 2.381

Review 2.  Clinical, psychological, and genetic characteristics of spinocerebellar ataxia type 19 (SCA19).

Authors:  H Jurgen Schelhaas; Bart P C van de Warrenburg
Journal:  Cerebellum       Date:  2005       Impact factor: 3.847

3.  Consensus paper: the cerebellum's role in movement and cognition.

Authors:  Leonard F Koziol; Deborah Budding; Nancy Andreasen; Stefano D'Arrigo; Sara Bulgheroni; Hiroshi Imamizu; Masao Ito; Mario Manto; Cherie Marvel; Krystal Parker; Giovanni Pezzulo; Narender Ramnani; Daria Riva; Jeremy Schmahmann; Larry Vandervert; Tadashi Yamazaki
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

Review 4.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

5.  Cognitive dysfunction in patients with spinocerebellar ataxia type 6.

Authors:  Itaru Tamura; Asako Takei; Shinsuke Hamada; Michio Nonaka; Yoshiko Kurosaki; Fumio Moriwaka
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

6.  A toolbox to visually explore cerebellar shape changes in cerebellar disease and dysfunction.

Authors:  S Mazdak Abulnaga; Zhen Yang; Aaron Carass; Kalyani Kansal; Bruno M Jedynak; Chiadi U Onyike; Sarah H Ying; Jerry L Prince
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2016-03-24

7.  Resting-state functional connectivity and cognitive dysfunction correlations in spinocerebelellar ataxia type 6 (SCA6).

Authors:  Licia Pereira; Raag D Airan; Ann Fishman; Jay J Pillai; Kalyani Kansal; Chiadi U Onyike; Jerry L Prince; Sarah H Ying; Haris I Sair
Journal:  Hum Brain Mapp       Date:  2017-03-15       Impact factor: 5.038

8.  Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6.

Authors:  Ina Klinke; Martina Minnerop; Tanja Schmitz-Hübsch; Marc Hendriks; Thomas Klockgether; Ullrich Wüllner; Christoph Helmstaedter
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

9.  Cognitive and social cognitive functioning in spinocerebellar ataxia : a preliminary characterization.

Authors:  P Garrard; N H Martin; P Giunti; L Cipolotti
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

10.  Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6 : a voxel-based FDG-positron emission tomography analysis.

Authors:  Po-Shan Wang; Ren-Shyan Liu; Bang-Hung Yang; Bing-Wen Soong
Journal:  J Neurol       Date:  2007-04-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.